Location
The Booth Presentations are scheduled during the breaks of all 3 days of the Symposium, in dedicated booths dispatched in the two foyer and exhibition areas.
For all attendees (and especially the remote attendees), the PDF of the presentations will be available on the virtual portal.
Floor map & Schedule
Please note all timings are based on Beijing time zone.
➜ China Standard Time (CST) – UTC+8
20261102161254
Slideshow on Displays
These presentations are only available on dedicated TV Booths during the whole meeting, and/or through the virtual portal.
No oral presentation is scheduled for this selection:
| Abstract | Author/Presenter |
| #2006 | Prajwal PUDASAINI Epidemiology of Atopic Dermatitis in Nepalese Population: Exploring the varied presentations in skin of color patients in diverse terrains |
| #2021 | Gautier DOAT Characterization of patients with moderate-to-severe atopic dermatitis controlled by systemic treatments, their needs and expectations regarding emollient use |
| #2024 | Jensen YEUNG Real-world experience of abrocitinib for atopic dermatitis: A 16-week multicenter retrospective study |
| #2027 | Christabel Avwerosuoghene OVESUOR Seasonal Dynamics and Healthcare Utilisation in Atopic Dermatitis: A Retrospective Analysis from a Tertiary Hospital in Delta State, Nigeria |
| #2028 | Christabel Avwerosuoghene OVESUOR Bridging the Melanin Gap: Artificial Intelligence in the Diagnosis of Atopic Dermatitis in African Skin—A Narrative Review |
| #2033 | Xia DOU A murine model of prurigo nodularis-like skin lesions induced by persistent scratching under type 2 inflammatory conditions |
| #2043 | Shahil LODHIA Delgocitinib cream improves pain and health-related quality of life in patients with Chronic Hand Eczema with severe pain |
| #2044 | Vimal H PRAJAPATI Interpreting 1.5% Ruxolitinib Cream Efficacy in a Canadian Treat-to-Target Framework |
| #2046 | Nam Gyoung HA Itch–Lesion Dissociation in Atopic Dermatitis: Prevalence, Predictors, and Differential Treatment Response of the Itch-Dominant Phenotype |
| #2047 | Xia DOU Metabolic Profiling of Staphylococcus aureus in Atopic Dermatitis: Implications for Disease Severity and Pruritus |
| #2050 | Jianzhong ZHANG Itch Control of MG-K10 in adults with moderate to severe atopic dermatitis: a post-hoc analysis of a phase III clinical trial |
| #2051 | Siying RUAN Dupilumab Combined with a Multi-Targeted Barrier Repair Cream in Severe Atopic Dermatitis with Comorbid Malignancy and Multisystem Disease: A 12-Week Case Report |
| #2056 | Ying YE Postbiotics Emollient and Risk of Relapse in Pediatric Atopic Dermatitis: A Randomized Trial |
| #2057 | Bark-Lynn LEW Effectiveness and safety of systemic Janus kinase inhibitors for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab: A real-world retrospective study |
| #2065 | Tae Young HAN A Study on the Characteristics and Comorbidities of Severe Adult Atopic Dermatitis: A Nationwide Population-based Study |
| #2067 | Xuan WANG Patients with Atopic Dermatitis with a Stable Response to Lebrikizumab Flare Less in a Long-Term Study: A Post-hoc Analysis of the ADjoin Study |
| #2068 | Xuan WANG Patients maintain stable response with no or minimal fluctuations during 3 years of continuous treatment with lebrikizumab during long-term extension trial |
| #2070 | Yun-Ji LEE Real-World Switching Patterns and Predictors of Treatment Response to Advanced Therapies in Atopic Dermatitis |
| #2077 | Yun-Ji LEE Dermatologic Comorbidities in Patients with Atopic Dermatitis Compared with Psoriasis: A Two-Center Retrospective Study |
| #2081 | Ziying GUO Nickel Sensitization Is Not Associated with Atopic Dermatitis: A Meta-Analysis |
| #2086 | Dr. Maria ANSARI Sulphates and Parabens in Atopic Dermatitis: Reassessing Ingredient Avoidance in the Era of Clean Beauty |
| #2088 | Yayi SUN Real-World Utilization and Effectiveness of Upadacitinib in Atopic Dermatitis: 12-Month Interim Analysis of the 500 Chinese Patients in REACH-AD Study |
| #2091 | Naina Harinjara RAZANAKOTO Therapeutic inadequacy prior to specialist consultation in atopic dermatitis among outpatients seen at the dermatology department of the university hospital Mahavoky Atsimo of Mahajanga, Madagascar |
| #2092 | Berenice DEGBOE Adult atopic dermatitis on West African pigmented skin: epidemiological and clinical phenotype |
| #2100 | Tracy Chen Qin XU A Systematic Review of the Long-Term Effectiveness of Oral JAK1 Inhibitors in the Treatment of Chronic Hand Eczema |
| #2105 | Xia WU Validation of IGA×BSA in Assessing Disease Severity and Response in Patients with Atopic Dermatitis |
| #2108 | Jianzhong ZHANG Efficacy and Safety of Direct Switching to Manfidokimab, a Novel Anti-IL-4Rα Monoclonal Antibody, in Patients with Moderate-to-Severe Atopic Dermatitis Currently Receiving Biologics or JAK Inhibitors |
| #2109 | Xia WU miRNA detected in plasma-derived exosomes reveals differentially expressed miRNAs Related to atopic dermatitis |
| #2112 | Shahil LODHIA Construction and validation of a photographic guide for the validated Investigator’s Global Assessment of Chronic Hand Eczema scale (IGA-CHE) |
| #2113 | Shahil LODHIA Real-world effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema: interim analysis after 8 weeks of treatment in the German REACHED study |
| #2114 | Shahil LODHIA Treatment with delgocitinib cream is associated with reductions in Staphylococcus aureus density and pain, and increased microbial diversity in patients with mild to severe Chronic Hand Eczema |
| #2122 | Jung Eun KIM Effectiveness and Safety of Tralokinumab in Korean Patients with Atopic Dermatitis: A Multicenter Retrospective Study |
| #2124 | Brenda NGO When Guidelines Meet Real-World Risk: Tuberculosis During Dupilumab Therapy in Severe Atopic Dermatitis |
| #2127 | Yijie ZHENG Efficacy and Safety of Moisturizing Cream containing EOP(1), NP(3), & AP(6-II) as Adjuvant Therapy in Adult Patients with Mild Atopic Dermatitis: A Multicenter, Randomized, Parallel-Controlled Trial |
| #2131 | Xiaoye NIU Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and food effect (FE) of QLS12010, a novel oral interleukin-1 receptor–associated kinase 4 (IRAK4) degrader in healthy participants (HPs): A double-blind, randomized phase 1 study |
| #2132 | Jianzhong ZHANG Enhanced Efficacy After Dosing Interval Extension of Stapokibart in Fast Responders With Moderate-to-Severe Atopic Dermatitis Regardless of Prior Systemic Therapy |
| #2133 | Jianzhong ZHANG Extended-Interval Stapokibart in Atopic Dermatitis Patients with and without Type 2 Inflammatory Comorbidities: A Post-Hoc Analysis of a Phase 2 Trial |
| #2140 | Ana B. ROSSI Dupilumab Monotherapy for 1 Year Provides Rapid and Sustained Improvement in SCORAD Across Dose Regimens in Adults With Moderate-to-Severe Atopic Dermatitis |
| #2142 | Peimei ZHOU Exploring Oral Microbiome and Metabolic Characteristics of Atopic Dermatitis in Children and Adolescents Using Salivary Metagenomics and Metabolomics |
| #2156 | Xiaoya MA PVP/NaB-Loaded Dissolving Microneedles Suppress Macrophage-Driven CCL3–PI3K/AKT Signaling and Restore Skin Barrier Function in Atopic Dermatitis |
| #2159 | Wei ZHU A Case Report on the Adjunctive Use of an Oil-Control and Soothing Emulsion Containing Niacinamide and Silymarin Complex in Improving Oily, Sensitive Skin |
| #2168 | Zenan TANG Short chain fatty acids alleviate atopic dermatitis associated itch by regulating basophil activation and mitochondrial lipid droplet homeostasis |
| #2169 | Zenan TANG Performance Evaluation of Large Language Model Chatbots for Atopic Dermatitis Patient Education |
| #2171 | Yu WANG Early Transcriptomic Remodeling and Molecular-Inflammatory Trajectories Define Long-Term Response to Abrocitinib in Atopic Dermatitis |
| #2172 | Chaoying GU Clinical and inflammatory determinants of successful abrocitinib dose reduction in atopic dermatitis: a real-world cohort study with implications for treatment optimization |
| #2186 | Jensen YEUNG Efficacy Outcomes of Abrocitinib in Adult Patients With Moderate-to-Severe Atopic Dermatitis Using Canadian Treat-to-Target Criteria |
| #2190 | Lin MA Real-World Sustained Improvement in Type 2 Inflammatory Comorbidities with Dupilumab in Chinese Pediatric and Adolescent Patients with Atopic Dermatitis: 52-Week Results from the ADOPED-STAD Observational Stud |
| #2191 | Yumei LIU Inflammatory memory in atopic dermatitis recurrence: a comprehensive review of cellular and molecular mechanisms |
| #2194 | Jie YANG Dupilumab in atopic dermatitis combined with acquired reactive perforating collagenosis: A potential new treatment |
| #2196 | Jung Jin SHIN Real-World Effectiveness of Lebrikizumab in Korean Patients with Severe Atopic Dermatitis: A 16-Week Retrospective Analysis |
| #2202 | Abdul Mannan MUSTAFA The CLEAR-AD Framework: A Personalized Barrier-Directed Care Model for Childhood Atopic Dermatitis in Underserved Communities |
| #2207 | Chan-Ho NA Real-world efficacy, safety, and treatment patterns of switching advanced therapies in patients with moderate-to-severe atopic dermatitis: A single-centre study |
| #2208 | Yuanyuan TIAN Validation of the AD prevention Effect of an Oat-Containing Balm Using an In Vitro Skin Model of Newborns |
| #2215 | Yi XUE The Multidimensional Burden of Atopic Dermatitis in Chinese Children and Adolescents: A Regional Multicenter Survey in Zhejiang Province |
| #2219 | Yan LIU The Impact of Dupilumab on Skin Barrier-Related Protein and Microbiota in Children Aged 6-12 Years with Moderate-to-Severe Atopic Dermatitis |
| #2226 | Yunqing REN The effect of ease of skin tanning, childhood sunburn, sun/UV protection on atopic dermatitis is related to the skin microbiota: evidence from two-step mendelian randomisation studies |
| #2227 | Yan YANG Effect of CFTR-Regulated Th17 Cell Activation on the Skin Barrier in Atopic Dermatitis |
| #2236 | Wei LI Improvement of atopic dermatitis-associated lichen amyloidosis following stapokibart treatment: a case report |
| #2238 | Jinxiang YANG Pediatric IPEX-Associated Dermatitis Responds to Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling |
| #2241 | Yifeng GUO Benzalkonium Chloride-Associated Granular Parakeratosis Mimics Atopic Dermatitis and Reveals Environmental Exposure-Driven Inflammatory Keratinocyte Remodeling |
| #2245 | Vimal H PRAJAPATI Real-world experience of lebrikizumab for atopic dermatitis: A 16-week multicenter retrospective study |
| #2246 | Ying ZOU A Pilot Study to Establish an Ovalbumin-induced Atopic Dermatitis Chronic Recurrence Mouse Model |
| #2251 | Liping DONG Gold Nanoparticles-Embedded Mn/Zn-MOF with Enhanced Antioxidant Activities for Treating Atopic Dermatitis |
| #2253 | Fuchen HUANG Proteomic Profiling Differentiates Erythrodermic Atopic Dermatitis from Erythrodermic Psoriasis: A Novel insight of CD99 molecule |
| #2263 | Di WANG 4-Octyl itaconate attenuates atopic dermatitis by inhibiting macrophage ferroptosis via the Nrf2/GPX4 pathway |
| #2265 | Jiawen CHEN Maternal caffeinated beverage consumption during pregnancy and the risk of infantile atopic dermatitis during the first year of life |
| #2269 | Hongqing ZHAO MrgprD + non-peptidergic neurons regulate mast cells via galectin-3 to contribute to itch in atopic dermatitis |
| #2273 | Hui-Chun SU An Evaluation of Differences in the Efficacy of Dupilumab in Treating Patients with Moderate-to-Severe Atopic Dermatitis, With or Without Facial Dermatitis, Based on CBS Multispectral Examination |
| #2274 | Liya MAO Opsin 3 in keratinocytes mediates the light-induced exaggeration of atopic dermatitis |
| #2275 | Stevy DESANA Atopic Dermatitis Associated with Nutritional Rickets in a Child: A Case Report |
| #2276 | Xiao Chuan TIAN Epidermal BMP2/BMP4 Deficiency Disrupts Skin Barrier Homeostasis |
| #2279 | Fang WANG Dose-Response Relationship of Radiotherapy in Hand and Foot Eczema: A Retrospective Cohort Study |
| #2283 | Jinping YUAN A Case Report: Stapokibart for Refractory Head and Neck Lesions of Moderate-to-Severe Atopic Dermatitis with Poor Response to Dupilumab |
| #2287 | Xiaojie WANG Tapinarof attenuates MC903-caused atopic dermatitis in mice and decreased TNF-alpha/IFN-gamma-induced cytokines through downregulation of Endothelial lipase G-NF-kappa B pathway in HaCaT cells |
| #2290 | Zhuoqiong QIU Sebum-induced type 17 inflammatory milieu underpins the body-site heterogeneity of atopic dermatitis |
| #2301 | Qiuyu JIA Malassezia globosa Induces Differentiation of Pathogenic Th17 Cells by promoting IL-23 Secretion of Keratinocytes via FABP5 in Head-and-neck dermatitis |
| #2309 | Zhu WEI Clinical Efficacy and Safety of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Young Children Aged 6 Months to 6 Years: A Single-Center Study |
| #2310 | Yue DONG Environmental Heat Exacerbates Atopic Dermatitis Through TRPV1 Activation: Protective Effects of Capsazepine |
| #2317 | Yunqing REN Effectiveness and Safety of Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Infants, Children, and Adolescents: A Real-World Study |
| #2320 | Yunqing REN Relationship between atopic dermatitis and obesity at different ages |
| #2323 | Li MA Molecular Mechanisms of Fire Needling Therapy in Dermatological Diseases: A Review |
| #2324 | Zheng LI Long-Term Real-World Effectiveness, Drug Retention and Safety of Upadacitinib, Abrocitinib and Dupilumab for Atopic Dermatitis |
| #2325 | Yan ZHAO Senescent Fibroblast Promote M1 Macrophage Polarization via Metabolic Reprogramming: Implications for Aging-Related Atopic Dermatitis |
| #2328 | Bingxue BAI Efficacy and Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study in Chinese Patients |
| #2330 | Li MA Smart EASI: An AI-Powered System for Standardized and Efficient Atopic Dermatitis Severity Assessment |
| #2331 | Yirong HUANG Dupilumab for the treatment of atopic dermatitis in a pediatric liver transplant recipient: a case report and literature review |
| #2333 | Yangyongyi ZONG Mycosis Fungoides Localized to a Single Palm |
| #2341 | Ting PAN Vigilance for Lymphoma Risk in the Diagnosis and Treatment of Atopic Dermatitis |
| #2345 | Peter SCHMID-GRENDELMEIER Dietary Habits and Atopic Dermatitis Significantly Influence the Fecal Microbiome |
| #2346 | Li MA Pediatric Atopic Dermatitis Incidence: Driven by Genes and Environment |
| #2355 | Lydie Joelle SEUDJIP NONO Prevalence and Factors Associated with Food Allergen Sensitization Detected by Skin Prick Testing in Congolese Children with Atopic Dermatitis: A Cross-Sectional Study of 102 Patients at the North Kivu Provincial Hospital, 2025 |
| #2371 | Londiwe Nokujabula BUTHELEZI The level of natural moisturising factors in the stratum corneum of African atopic dermatitis patients in KwaZula-Natal, South Africa. |
| #2376 | Anna BELLONI FORTINA Cleansing Atopic Skin |
| #2377 | Silvia M. FERRUCCI Comparison of Two Eye Drops for Keratoconjunctivitis Prevention in Atopic Dermatitis Patients Treated with Biologics |
20261102161254
Submissions rejected or cancelled
| Abstract | Author/Presenter |
| #2040 | XD |
| #2054 | JJ |
| #2079 | TC |
| #2082 | YZ |
| #2101 | ANO |
| #2117 | ADI |
| #2128 | JZ |
| #2130 | GCF |
| #2144 | LJ |
| #2154 | ONH |
| #2161 | LM |
| #2166 | GD |
| #2173 | JP |
| #2184 | LM |
| #2189 | LW |
| #2195 | LW |
| #2204 | MZ |
| #2205 | QZ |
| #2209 | XW |
| #2211 | YL |
| #2221 | YR |
| #2225 | KG |
| #2239 | LZ |
| #2242 | YL |
| #2255 | XL |
| #2271 | YL |
| #2272 | PS |
| #2282 | LM |
| #2284 | YL |
| #2286 | FW |
| #2293 | YG |
| #2295 | XL |
| #2296 | YL |
| #2297 | YR |
| #2300 | YG |
| #2302 | YL |
| #2305 | YG |
| #2306 | LM |
| #2307 | JJ |
| #2308 | WL |
| #2313 | ZS |
| #2321 | LM |
| #2334 | AAA |
| #2335 | YG |
| #2337 | YZ |
| #2343 | XX |
| #2354 | LJS |
| #2362 | LM |
| #2365 | XT |
20261102161254